Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...

Caris remains committed to advancing cancer diagnostics and treatment through innovative technologies and rigorous scientific ...

AbbVie has received accelerated approval from the U.S. Food and Drug Administration (FDA) for EMRELIS (telisotuzumab ...

Clinical results have revealed the effect of laser tinib, a third-generation EGFR targeted treatment, on atypical EGFR gene ...

The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...

Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients ...